Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002 …

PA LeWitt, M Guttman, JW Tetrud, PJ Tuite… - Annals of …, 2008 - Wiley Online Library
Objective Based on new understanding of nondopaminergic pathways involved in
Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist …
被引用次数：405 相关文章

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces" off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US …

PA LeWitt, M Guttman, JW Tetrud, PJ Tuite, A Mori… - 2008 - pubmed.ncbi.nlm.nih.gov
Objective Based on new understanding of nondopaminergic pathways involved in
Parkinson's disease (PD) pathophysiology, a selective adenosine A (2A) receptor …

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US …

PA LeWitt, M Guttman, JW Tetrud, PJ Tuite… - Annals of …, 2008 - experts.umn.edu
Objective: Based on new understanding of nondopaminergic pathways involved in
Parkinson's disease (PD) pathophysiology, a selective adenosine A 2A receptor antagonist …

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces" off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US …

PA LeWitt, M Guttman, JW Tetrud, PJ Tuite… - Annals of …, 2008 - europepmc.org
Objective Based on new understanding of nondopaminergic pathways involved in
Parkinson's disease (PD) pathophysiology, a selective adenosine A (2A) receptor …

Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002 …

PA LeWitt, M Guttman, JW Tetrud, PJ Tuite, A Mori… - Annals of …, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Objective</jats: title>< jats: p>
Based on new understanding of nondopaminergic pathways involved in Parkinson's …

[引用][C] Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces Off'Time in Parkinson's Disease: A Double-Blind, Randomized, Multicenter Clinical Trial …

PA LEWITT, M GUTTMAN, JW TETRUD… - Annals of …, 2008 - pascal-francis.inist.fr
Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces Off' Time in
Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005) …